Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

被引：0
作者：
Goto, Y. [1 ]
Yamamoto, N. [2 ]
Masters, E. [3 ]
Kikkawa, H. [4 ]
Mardekian, J. [3 ]
Wiltshire, R. [5 ]
Togo, K. [4 ]
Ma, H. [6 ]
Ohe, Y. [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Wakayama Med Univ, Dept Internal Med, Wakayama, Japan
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Japan Inc, Tokyo, Japan
[5] Pfizer Inc, Tadworth, England
[6] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK-positive NSCLC; treatment sequencing; tyrosine kinase inhibitor;
D O I：
10.1016/j.jtho.2018.08.1590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-30
引用
收藏
页码：S878 / S879
页数：2
相关论文
共 50 条
  • [41] ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis
    Ahn, Hee Kyung
    Han, Boram
    Lee, Su Jin
    Lim, Taekyu
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    LUNG CANCER, 2012, 76 (02) : 253 - 254
  • [42] RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
    Novello, Silvia
    Califano, Raffaele
    Reinmuth, Niels
    Tamma, Antonella
    Puri, Tarun
    ONCOLOGIST, 2023, 28 (05) : 402 - 413
  • [43] Afatinib for the treatment of metastatic non-small cell lung cancer
    Joshi, Monika
    Rizvi, Syed M.
    Belani, Chandra P.
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 75 - 82
  • [44] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [45] Afatinib treatment in advanced non-small cell lung cancer
    Hurwitz, Jane L.
    Scullin, Paula
    Campbell, Lynn
    LUNG CANCER-TARGETS AND THERAPY, 2011, 2 : 47 - 57
  • [46] Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
    Rath, Barbara
    Plangger, Adelina
    Hamilton, Gerhard
    CANCER DRUG RESISTANCE, 2020, 3 (02) : 171 - 178
  • [47] EXPLORATORY SUBGROUP ANALYSIS OF CRIZOTINIB EFFICACY AND SAFETY IN ASIAN AND NON-ASIAN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) ENROLLED IN A GLOBAL PHASE II STUDY
    Hida, Toyoaki
    Shi, Yuankai
    Ahn, M-J
    Liu, Xiaoquing
    Shaw, A. T.
    Yang, P-C
    De Pas, T. M.
    Han, J-Y
    Satouchi, M.
    Lanzalone, S.
    Polli, A.
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S454 - S455
  • [48] Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer
    Wozniak, Antoinette
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 (02) : 200 - 212
  • [49] Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
    Won, Brian
    Mambetsariev, Isa
    Salgia, Ravi
    BMC CANCER, 2016, 16
  • [50] Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)
    Popat, Sanjay
    Liu, Geoffrey
    Lu, Shun
    Song, Gregory
    Ma, Xin
    Yang, James Chih-Hsin
    FUTURE ONCOLOGY, 2021, 17 (32) : 4237 - 4247
12345